LTI
2.8.2022 11:02:08 CEST | Business Wire | Press release
Larsen & Toubro Infotech (BSE: 540005, NSE: LTI ), a global technology consulting and digital solutions company, has announced the expansion of its collaboration with Microsoft to focus on developing high-value cloud solutions for enterprises. As a part of this multi-year collaboration, LTI has launched a dedicated Microsoft business unit that develops and offers end-to-end digital transformation solutions.
Through this association, LTI will also train 12,000 professionals from its existing workforce on various Microsoft technologies by 2024. The main objective of this effort is to enable skill development of LTI employees that are a part of the Microsoft unit and enhance their competencies across technologies like cloud, data, IoT and security.
Nachiket Deshpande, Chief Operating Officer, LTI, said, “LTI has a long-standing relationship with Microsoft as a strategic partner, service provider, and customer. Our reaffirmed partnership with Microsoft will enable us to innovate and offer 170+ distinct services to our joint customers. Additionally, we will also focus on the training and upskilling of our talent pool that is a part of the dedicated Microsoft business unit, to empower them to meet changing business and market requirements.”
Siddharth Bohra, Chief Business Officer & Head of Cloud Business Unit, LTI , said, “Enterprises across the globe are increasingly embracing cloud, and LTI has made impressive strides in developing a multi-dimensional capability on Azure to meet this demand. As part of this collaboration, LTI and Microsoft will jointly innovate, develop, and sell solutions to assist enterprises in acceleration of their digital transformation journeys.”
Julie Sanford, Vice President, Partner GTM, Programs & Experiences, Microsoft , said, “Through their new Microsoft Business Unit, LTI will be able to help customers implement cloud strategies and drive business transformation across industries and geographies. We look forward to working with LTI as they build new capabilities and deliver innovative solutions on the Microsoft Cloud.”
Through this association, LTI will attain the Solution Partner designation across all the Microsoft Solution Areas. LTI also has the following advanced specializations on Azure:
- SAP on Azure : Validating the capability of implementing SAP solutions on Azure.
- Analytics on Azure : Demonstrating the expertise in delivering analytics solutions in Microsoft Azure.
- Windows Server and SQL Server : Expertise in migrating production workloads to Microsoft Azure.
- Modernization of Web Applications : Validating expertise in migrating and deploying production web application workloads, applying DevOps, and managing app services in Microsoft Azure.
- Kubernetes on Azure : validating capabilities in deploying and managing production workloads in the cloud using containers and managing hosted Kubernetes environments in Azure.
- Low Code Application Development : Expertise in building solutions using Power Apps.
- The Data Warehouse Migration to Microsoft Azure : Validating expertise in analyzing existing workloads and performing ETL operations to migrate data to cloud-based data warehouses.
- Cloud Security : Validates a means for your company to showcase capabilities to implement comprehensive security solutions across Azure, hybrid, and multi-cloud environments.
- Threat Protection : provides a means for your company to showcase proven, verifiable expertise in deploying Microsoft Threat Protection or Microsoft Cloud App Security workloads.
- AI and Machine Learning in Microsoft Azure : Validates capabilities on enabling customer adoption of Al and implementing Azure solutions for Al-powered apps.
LTI is an Azure Expert MSP Partner which demonstrates deep knowledge, extensive experience, and proven success in implementing specialized workloads such as Migration and Modernization, SAP on Azure, Data Analytics, Internet of things (IoT), Security, and Microsoft Dynamics 365.
About LTI:
LTI (NSE: LTI ) is a global technology consulting and digital solutions Company helping more than 495 clients succeed in a converging world. With operations in 33 countries, we go the extra mile for our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 46,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Find more at https://www.lntinfotech.com or follow us at @LTI_Global .
Connect with LTI:
Read More:
- LTI Becomes Microsoft Azure Expert Managed Services Provider
- LTI has Earned the Kubernetes on Microsoft Azure Advanced Specialization
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005516/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom